Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Trimazosin

Home DrugsTrimazosin

Experimental

Small Molecule

Trimazosin

Unknown Manufacturer

Trimazosin is a sympatholytic alpha blocker.

Generate AI report

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Overview

Trimazosin is a sympatholytic alpha blocker.

Indications

用于治疗高血压及心力衰竭。现已少用。

Technical identifiers

Chemical Formula: C₂₀H₂₉N₅O₆
CAS Number: 35795-16-5
UNII ID: 31L760807H

Patents

One entry per invention. Patent families filed in the US, EP, WO and CN offices.

EYEDROPS CONTAINING AN ALPHA1-BLOCKER FOR INHIBITING MYOPIA PROGRESSION
US 20250222008 A1Applicant: TSUBOTA LAB INCPriority: 2022
US